PyInvesting

Market research

RSLS ReShape Lifesciences Inc

NASDAQ USD Healthcare

Latest close

Loading market data…

Test a moving-average rule with historical data.

Market cap
9M
P/E ratio
Not available
Analyst target
1
Dividend yield
Not available
Beta
1.9

Community

Investor discussion

1 comment

Admin profile picture
Admin

5 years, 4 months ago

From a valuation standpoint, the stock is 99.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.2.

Based on the above factors, ReShape Lifesciences Inc gets an overall score of 1/5.